ClinicalTrials.Veeva

Menu

Addition of MgSO4 or Dexamethasone to Bupivacaine on the Prolongation of Ultrasound-guided Quadratus Lumboram Block

A

Ain Shams University

Status

Completed

Conditions

Post Operative Pain

Treatments

Drug: Bupivacaine- Magnesium
Drug: Bupivacaine saline
Drug: Bupivacaine dexamethasone

Study type

Interventional

Funder types

Other

Identifiers

NCT05397236
FMASU MS 256/2021

Details and patient eligibility

About

The goal of postoperative pain management is the provision of comfort, early mobilization and improved respiratory function without causing inadequate sedation and respiratory compromise, which can be achieved through using regional anethesia.

This study aimed to assess the analgesic effect of adding dexamethasone or magnesium sulphate with bupivacaine in ultrasound-guided QLB to prolong its duration in patients undergoing open abdominal surgeries in the early postoperative period regarding pain relief After approval of the ethical committees in Ain Shams University Hospitals, patients undergoing open abdominal surgeries were included in the study, and were divided into three groups (n=22; each); group M, D and group C. In Group A, patients (n=22) received 20 ml bupivacaine 0.25% plus 5 ml of 10% MgSO. In group B, patients (n=22) received 20 ml bupivacaine 0.25% plus 8 mg dexamethasone (2 ml) plus 3 ml 0.9% NaCl. In group C (control), patients (n=22) received 20 ml bupivacaine plus 5 ml 0.9% NaCl.

Enrollment

66 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • American Society of Anesthesiologists (ASA) physical status I or II
  • aged 18 to 65 years
  • body weight ≥ 60 kg and ≤ 90 kg
  • scheduled for open abdominal surgeries

Exclusion criteria

  • Patients' refusal to participate in the study
  • history of allergy to the medications used in the study
  • hepatic disease
  • renal disease
  • known neurologic disorders
  • psychiatric disorder
  • chronic treatment with calcium channel blockers
  • hyper-magnesemia
  • coagulopathy
  • anatomical abnormalities
  • hemodynamic instability
  • local infection
  • suspected intra- abdominal sepsis

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

66 participants in 3 patient groups

Bupivacaine Magnesium sulphate group
Active Comparator group
Description:
Patients received QL block with 20 ml of 0.25% bupivacaine (2, 4)plus 5 ml of 10% MgSO4.
Treatment:
Drug: Bupivacaine- Magnesium
Bupivacaine Dexamethasone group
Active Comparator group
Description:
Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 2 ml of 8 mg dexamethasone plus 3 ml of 0.9% NS.
Treatment:
Drug: Bupivacaine dexamethasone
bupivacaine saline group
Active Comparator group
Description:
Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 5 ml of 0.9% NS.
Treatment:
Drug: Bupivacaine saline

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems